See the DrugPatentWatch profile for Ertapenem
Ertapenem 500 mg IV cost can vary significantly depending on factors such as the pharmacy, insurance coverage, and location. It is generally considered a more expensive antibiotic, with prices ranging from approximately $70 to over $150 per dose for the 500 mg vial [1].
What influences the price of Ertapenem?
The cost of Ertapenem is influenced by several factors. These include the drug's manufacturing costs, research and development expenses, and the pricing strategies of pharmaceutical companies. For healthcare providers and patients, insurance formularies and formulary placement play a crucial role in determining the out-of-pocket expense. Additionally, the availability of generic versions can impact pricing, though for newer or specialty drugs, branded versions often remain dominant for a period.
Are there cheaper alternatives to Ertapenem?
While Ertapenem is a broad-spectrum carbapenem antibiotic, other antibiotic classes may be considered as alternatives depending on the specific infection and its susceptibility profile. These alternatives might include other beta-lactams, fluoroquinolones, or combination therapies. However, the choice of an alternative is guided by clinical guidelines, bacterial resistance patterns, and patient factors like allergies and comorbidities. The cost of these alternatives can also vary widely.
When does Ertapenem's patent expire?
Information on the specific patent expiry dates for Ertapenem is available through resources that track drug patents. Companies like DrugPatentWatch.com provide detailed patent landscape information, which can help determine when market exclusivity for branded Ertapenem might end, potentially paving the way for generic competition [2].
What is Ertapenem used for?
Ertapenem is a carbapenem antibiotic used to treat moderate to severe infections caused by susceptible bacteria. This includes infections of the abdomen, skin and skin structure, lungs, and certain types of pelvic or vaginal infections. It is administered intravenously [3].
Who manufactures Ertapenem?
Ertapenem is marketed under the brand name Invanz by Merck & Co. [4]. Generic versions may be manufactured by other pharmaceutical companies following patent expiry.
What is the typical dosage and administration of Ertapenem?
The recommended dose for adults is 1 gram administered intravenously once daily. For pediatric patients aged three months and older, the dose varies based on weight, typically 15 mg/kg every 12 hours. Treatment duration depends on the type and severity of the infection [3].
What are the potential side effects of Ertapenem?
Common side effects associated with Ertapenem include diarrhea, nausea, vomiting, headache, rash, and pain or redness at the injection site. More serious, though less common, side effects can include severe allergic reactions, Clostridioides difficile-associated diarrhea, and seizures [3].
How does Ertapenem compare to other carbapenems?
Ertapenem is a carbapenem antibiotic, a class known for its broad spectrum of activity against many Gram-positive and Gram-negative bacteria. Other carbapenems, such as imipenem, meropenem, and doripenem, share similar mechanisms of action but may differ in their spectrum of activity, pharmacokinetic profiles, and approved indications [5]. These differences can influence their use in specific clinical scenarios and their associated costs.
What clinical data supports Ertapenem's efficacy?
Clinical trials have demonstrated Ertapenem's efficacy in treating various types of bacterial infections. Studies have shown its effectiveness against complicated intra-abdominal infections, complicated skin and skin structure infections, community-acquired pneumonia, and gynecologic infections. The specific outcomes and patient populations studied are detailed in the drug's prescribing information and clinical literature [3].
Sources:
[1] https://www.goodrx.com/ertapenem
[2] https://drugpatentwatch.com/
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020971s047lbl.pdf
[4] https://www.merck.com/
[5] https://www.ncbi.nlm.nih.gov/books/NBK557815/